Clinical Trial Update: Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 trial update on adoptive immunotherapy using activated marrow-infiltrating lymphocytes with cyclophosphamide for GVHD prophylaxis in relapsed hematologi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Hematologic Malignancies

Drugs mentioned

• Activated marrow infiltrating lymphocytes (activated marrow infiltrating lymphocytes)
• CYCLOPHOSPHAMIDE (Cyclophosphamide)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Hematologic Malignancies, Graft-Versus-Host Disease | Phase 1 | Status: COMPLETED